Loading
Arbutus Biopharma Corp Stock: price and insider trades · United States
Arbutus Biopharma Corp: what insiders have been doing
Arbutus Biopharma Corp, founded in 2007, is a Healthcare & Pharma company based in Burnaby, Canada. Its directors and officers file their transactions with SEC (Form 4). 5 insiders have disclosed 19 filings since 18 October 2025.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
No insider has bought Arbutus Biopharma Corp shares on the open market in the past twelve months. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 5 days. US insiders must file a Form 4 within two business days of a trade.
Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 19 filings, this issuer sits right on that mark. Over the whole record (from 2021), the tally stands at no purchases and 5 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
40
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€1M
5 ops. · all time
Who traded when
BuySaleDavid C. Hastings1 sale
J. Christopher Naftzger1 sale
Karen Sims1 sale
Michael J. McElhaugh1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.11
Analyst consensus
1 analysts1.00/5
US$5.37Target US$5.37(+31%)US$5.37
Income statement
RevenueUS$14.1M
EBITDA-US$33M-235% margin
Net income-US$33.5M84.2% margin
Valuation
PER (trailing)5.2x
P/Book3.1x
Beta0.76
Balance sheet & cash
Market capUS$630M
Total debtUS$746k
Free Cash Flow-US$39.6M
Debt / Equity1%
Profitability & ownership
ROE89.6%
ROA48.8%
% insiders15.9%
% institutions66.9%
Last declaration on 7 October 2026
Declarations40 total
17,948 shares@ US$5.000.012% mcap8.3% of flowCommon SharesSEC:0001447028-26-000061:0
48,081 shares@ US$5.000.033% mcap10.4% of flowCommon SharesSEC:0001447028-26-000060:0
17,142 shares@ US$5.000.012% mcap7.8% of flowCommon SharesSEC:0001447028-26-000059:0
24,655 shares@ US$5.000.017% mcap13.0% of flowCommon SharesSEC:0001447028-26-000058:0
8,967,383 shares@ US$5.005.04% mcap100.0% of flowCommon SharesSEC:0001140361-26-038692:0
116,408 shares@ US$3.200.038% mcap44.5% of flowCommon SharesSEC:0001447028-26-000053:0
82,527 shares@ US$5.070.043% mcap50.0% of flowCommon SharesSEC:0001447028-26-000053:2
78,800 shares@ US$4.240.034% mcap33.3% of flowCommon SharesSEC:0001447028-26-000050:1
100,508 shares@ US$5.070.053% mcap50.0% of flowCommon SharesSEC:0001447028-26-000051:2
265,625 shares@ US$3.490.096% mcap44.2% of flowCommon SharesSEC:0001447028-26-000052:0
27,475 shares@ US$4.390.012% mcap5.8% of flowCommon SharesSEC:0001447028-26-000052:1
206,637 shares@ US$5.070.11% mcap50.0% of flowCommon SharesSEC:0001447028-26-000052:2
10,456 shares@ US$4.390.0047% mcap5.5% of flowCommon SharesSEC:0001447028-26-000053:1
52,533 shares@ US$3.200.017% mcap16.7% of flowCommon SharesSEC:0001447028-26-000050:0
99,057 shares@ US$5.070.052% mcap50.0% of flowCommon SharesSEC:0001447028-26-000050:2
52,533 shares@ US$3.340.018% mcap17.2% of flowCommon SharesSEC:0001447028-26-000051:0
78,800 shares@ US$4.240.034% mcap32.8% of flowCommon SharesSEC:0001447028-26-000051:1
73,500 shares0Common SharesSEC:0001447028-26-000009:0
28,000 shares0Common SharesSEC:0001447028-26-000008:0
177,000 shares0Common SharesSEC:0001447028-25-000051:0
49,300 shares0Common SharesSEC:0001447028-25-000049:0
90,100 shares0Common SharesSEC:0001447028-25-000050:0
54,300 shares0Common SharesSEC:0001447028-25-000052:0
23,790 shares@ US$3.283100.0% of flowCommon SharesSEC:0001447028-25-000038:0
22,183 shares@ US$3.283100.0% of flowCommon SharesSEC:0001447028-25-000040:0
25 of 40 declarations
About Arbutus Biopharma Corp
Arbutus Biopharma Corp. (ticker: ABUS) is a U.S.-listed clinical-stage biopharmaceutical company traded on the Nasdaq market in the United States. For investors, it represents a focused biotech story rather than a diversified pharmaceutical platform: the company is centered on virology, with chronic hepatitis B (HBV) as its core therapeutic priority. Arbutus is headquartered in Warminster, Pennsylvania, and has built its identity around antiviral drug development and delivery technologies, especially lipid nanoparticle (LNP) science, which has become an increasingly strategic asset for the company. ([arbutusbio.com](https://www.arbutusbio.com/))
The company’s history dates back to Tekmira Pharmaceuticals, which adopted the Arbutus Biopharma name in 2015 as it sharpened its focus on finding solutions for chronic hepatitis B. That transition was more than cosmetic: it reflected a strategic narrowing toward HBV and toward combination regimens designed to attack the virus through multiple mechanisms. Arbutus now frames its development strategy through a “Suppress, Reduce, Boost” approach, aiming to block viral replication, reduce viral antigens, and stimulate the host immune response in a coordinated way. ([arbutusbio.gcs-web.com](https://arbutusbio.gcs-web.com/news-releases/news-release-details/tekmira-announces-launch-arbutus-biopharma-hepatitis-b-solutions?utm_source=openai))
Read moreShow less
The company’s lead clinical asset is imdusiran, an RNAi therapeutic designed for chronic HBV. Arbutus is also advancing AB-101, an oral PD-L1 inhibitor, in early-stage clinical testing. In recent company updates, management highlighted encouraging functional-cure signals in phase 2a studies of imdusiran, as well as favorable early safety and receptor-occupancy data for AB-101. This gives ABUS a classic clinical-biotech profile: high upside if data continue to improve, but meaningful execution and development risk if clinical responses plateau or safety/tolerability becomes an issue. ([arbutusbio.gcs-web.com](https://arbutusbio.gcs-web.com/news-releases/news-release-details/arbutus-reports-first-quarter-2025-financial-results-and))
A second major pillar of the investment case is intellectual property. Arbutus owns valuable LNP-related patents and technology, and those assets have been central to its litigation and licensing economics. In 2026, the company announced a global settlement with Moderna over alleged patent infringement tied to LNP delivery technology, with a large upfront payment expected later in the year. That settlement materially improved Arbutus’ financial profile and may support capital-return discussions, while the company also continues to support related legal efforts involving Pfizer/BioNTech through Genevant. ([investor.arbutusbio.com](https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-reports-fourth-quarter-and-year-end-2025-financial))
Geographically, Arbutus’ operational footprint is U.S.-based, with its headquarters in Pennsylvania, but its commercial relevance is global because chronic hepatitis B is a worldwide disease area and because its technology and patent disputes have implications across the broader nucleic-acid delivery ecosystem. In short, ABUS is a specialized infectious-disease biotech on Nasdaq in the United States, with a pipeline-led story supplemented by monetizable IP and major legal catalysts. ([arbutusbio.com](https://www.arbutusbio.com/))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
